CN Patent

CN101208303A — Cgrp受体拮抗剂

Assigned to Merck and Co Inc · Expires 2008-06-25 · 18y expired

What this patent protects

式(I)的化合物(其中变量R 1 、A、B、W、X、Y和Z如本文中所定义的)用作CGRP受体拮抗剂和用于治疗或预防其中涉及CGRP的疾病，例如头痛、偏头痛和丛集性头痛。本发明还涉及含有这些化合物的药用组合物和这些化合物与组合物在预防或治疗其中涉及CGRP的这样疾病中的用途。

USPTO Abstract

式(I)的化合物(其中变量R 1 、A、B、W、X、Y和Z如本文中所定义的)用作CGRP受体拮抗剂和用于治疗或预防其中涉及CGRP的疾病，例如头痛、偏头痛和丛集性头痛。本发明还涉及含有这些化合物的药用组合物和这些化合物与组合物在预防或治疗其中涉及CGRP的这样疾病中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN101208303A
Jurisdiction
CN
Classification
—
Expires
2008-06-25
Drug substance claim
No
Drug product claim
No
Assignee
Merck and Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.